Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Sells $1,564,744.00 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at $15,631,136. This trade represents a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Aurinia Pharmaceuticals Trading Up 1.3 %

NASDAQ:AUPH opened at $8.08 on Wednesday. The firm has a market capitalization of $1.16 billion, a P/E ratio of -53.86 and a beta of 1.22. The business has a 50 day simple moving average of $8.13 and a 200 day simple moving average of $7.85. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.67.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC grew its holdings in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $31,000. Finally, Natixis bought a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $49,000. 36.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.